Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 First-in-class PRS inhibitor being developed as a...
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across Korea and the U.S. Interim baseline characteristics to be presented at the 2025 KATRD...
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs....